Printer Friendly

Evotec establishes spin-off company in the field of nanoparticle-based therapeutics.

M2 EQUITYBITES-March 24, 2016-Evotec establishes spin-off company in the field of nanoparticle-based therapeutics

(C)2016 M2 COMMUNICATIONS http://www.m2.com

Evotec, a drug discovery alliance and development partnership company, has established a spin-off company in the field of nanoparticle-based therapeutics intended to treat immunological disorders.

It was reported yesterday that the new company is called Topas Therapeutics GmbH and it intends to build a range of clinical-stage development projects to treat autoimmune diseases.

The proceeds of the Series A funding are expected to allow Topas to expand and accelerate its proprietary liver-based tolerance induction platform and to progress with its own product development efforts in multiple autoimmune and inflammatory indications, including multiple sclerosis, into clinical proof-of-concept stage.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Mar 24, 2016
Words:129
Previous Article:Moberg Pharma signs development agreement with Cadila Pharmaceuticals.
Next Article:Artbit app transforms art experience with point-and-snap technology.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters